Adaptive Biotechnologies Corporation (ADPT)

NASDAQ: ADPT · USD

$28.4

+0.74 (+2.7%)· Recorded snapshot

Market cap	4.5B
Revenue (ttm)	308.1M
Net income (ttm)	-63.9M
EPS (ttm)	-$0.41
Shares out	159.6M
Volume	1,910,271
Beta	2.10

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 308.1M
Net income (ttm): -63.9M
EPS (ttm): -$0.41
Market cap: 4.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-38.8

P25 -113.8P50 -46.5P75 -0.9

ROIC-4.9

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All ADPT indicators

Market & fundamental data

Available fields

210

Groups with data

Currency

USD

Showing 210 of 210 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001478320
Company name	Adaptive Biotechnologies Corporation
Country	United States
Country code	US
CUSIP number	00650F109
Earnings date	2026-11-04
Earnings time	amc
Employees	624
Employees change	5
Employees growth	0.81%
Enterprise value	$4.6B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2009
In index	RUSSELL2000
Industry	Diagnostics & Research
IPO date	2019-06-27
Is primary listing	Yes
Is SPAC	No
ISIN number	US00650F1093
Last 10-K release date	2026-02-26
Last earnings date	2026-07-29
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$4.5B
Market cap category	Mid-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$28.40
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	ADPT
U.S. state	Washington
Website	https://www.adaptivebiotech.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-1.45%
EV/Sales	15.05x
FCF / EV yield	-0.52%
FCF yield	-0.52%
Forward EV/Sales	14.53x
Forward P/S	14.41x
Industry forward P/E	30.92x
Industry P/E	50.57x
P/B ratio	30.78x
P/S ratio	14.92x
Price / tangible book value	199.34x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-12.16%
EBITDA margin	-6.92%
Gross margin	46.94%
Operating margin	-12.16%
Pretax margin	-20.77%
Profit margin	-20.73%
Profit per employee	$-102,330
Revenue per employee	$493,720
ROA	-4.12%
ROA (5Y)	-13.29%
ROCE	-6.77%
ROE	-38.76%
ROE (5Y)	-43.39%
ROIC	-4.88%
SBC / revenue	15.91%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	2
Gross profit growth	263.05%
Gross profit growth (Q)	92.49%
Net income growth years	2
Revenue growth	50.13%
Revenue growth (Q)	21.53%
Revenue growth (QoQ)	0.96%
Revenue growth 3Y	17.56%
Revenue growth 5Y	18.22%
Revenue growth quarters	8
Revenue growth years	2

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-3M
Depreciation and amortization	$16.1M
EBIT	$-37.5M
EBITDA	$-21.3M
EPS	$-0.41
FCF per share	$-0.15
Financing cash flow	$173M
Free cash flow	$-24M
Free cash flow minus SBC	$-73.1M
Gross profit	$144.6M
Investing cash flow	$-25.3M
Net borrowing	$187.4M
Net cash flow	$126.7M
Net income	$-63.9M
Operating cash flow minus SBC	$-70M
Operating income	$-37.5M
Revenue	$308.1M
Stock-based compensation	$49M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	0.62
Book value per share	$0.90
Debt / equity	2.72
Goodwill	$119M
Interest coverage	-3.26
Long-term assets	$220.1M
Long-term liabilities	$402.3M
Net cash (debt)	$-38.8M
Net cash / market cap	-0.84%
Net debt / equity	0.26
Piotroski F-Score	4
Property, plant and equipment	$68.6M
Shareholders' equity	$150.7M
Tangible book value	$23.1M
Tangible book value per share	$0.14
Total assets	$640.7M
Total cash	$344.3M
Total debt	$410.5M
Total liabilities	$490M
WACC	14.67%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.54
Current assets	$420.6M
Current liabilities	$87.7M
Current ratio	4.79
Inventory turnover	17.3
Net working capital	$-2.6M
Quick ratio	4.51
Working capital	$332.9M
Working capital turnover	1.23

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-4.11%
Dividend yield	0%
Shareholder yield	-4.11%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$20.65
1D price change	2.66%
1M price change	-3.52%
1M total return	-3.52%
1W price change	12.1%
1W total return	12.1%
1Y price change	65.86%
1Y return CAGR	65.92%
1Y total return	65.86%
20-day SMA	$26.17
200-day SMA	$19.51
3M price change	25.98%
3M total return	25.98%
3Y price change	568.12%
3Y return CAGR	88.32%
3Y total return	568.12%
50-day SMA	$26.30
50-day SMA vs 200-day SMA	50over200
52-week high	$30.74
52-week high date	2026-10-06
52-week low	$12.00
52-week low date	2026-03-12
5Y price change	-12.25%
5Y return CAGR	-2.58%
5Y total return	-12.25%
6M price change	99.82%
6M total return	99.82%
All-time high	$71.25
All-time high date	2021-01-19
All-time low	$2.28
All-time low date	2024-04-19
Average true range (ATR)	$1.48
Average volume	2M
Beta (1Y)	0.29
Beta (2Y)	1.16
Beta (5Y)	2.1
Change from 52-week high	-7.63%
Change from 52-week low	136.63%
Change from all-time high	-60.15%
Change from all-time low	1,145.39%
Change from open	1.59%
Day's gap	1.05%
Dollar volume	$54.2M
High price	$29.00
Low price	$27.95
Monthly RSI	73.82
Open price	$27.95
Position in 52-week range	42.38%
Premarket change	-1.48%
Premarket close	$27.66
Premarket price	$27.25
Premarket volume	7.6K
Previous close	$27.66
Price vs 150-day SMA	37.48%
Price vs 20-day SMA	8.51%
Price vs 200-day SMA	45.54%
Price vs 50-day SMA	7.96%
Relative volume	0.97
Return from IPO open	-26.17%
Return from IPO price	44%
RSI	60.8
Sharpe ratio	1.03
Sharpe ratio (3Y)	1.16
Sharpe ratio (5Y)	0.29
Sortino ratio	1.69
Sortino ratio (3Y)	2.05
Sortino ratio (5Y)	0.53
Volume	1.9M
Weekly RSI	64.83
YTD price change	74.85%
YTD total return	74.85%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	125.5M
Float percentage	78.63%
Shares change (QoQ)	2.79%
Shares change (YoY)	4.11%
Shares held by insiders	2.58%
Shares held by institutions	80.24%
Shares outstanding	159.6M
Short % of float	9.44%
Short % of shares	7.42%
Short ratio	5.3 days

Deeper analysis on ADPT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ADPT report

Is a complete ADPT research report available?

No complete published report is available for Adaptive Biotechnologies Corporation (ADPT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Adaptive Biotechnologies Corporation (ADPT)

Price

Financial snapshot

Fair-value bridge

Latest news · ADPT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ADPT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ADPT

Frequently asked questions